


Vaccine Manufacturing and Procurement in Africa Study

Next Steps: Stages 2 and 3

AVMI AGM

Newlands, Southern Sun Hotel, Cape Town, 30th November 2016

VMIPA Study: Stage methodology overview



Note: The scope and execution of each stage will be dependant on funding and resources being available !

VMPA Study: *The Goal*



Provide an **analytical assessment** of vaccine **manufacturing** capacity and **procurement** mechanisms in Africa and suggest options for further **consideration**

Develop a pragmatic, **evidence based, guidance document** for established/new/interested African vaccine manufacturers to consider when establishing their investment plans wrt building vaccine/biological capacity

VMPPA Stage 1: Landscape Analysis Report

SCOPE

Focused on four priority areas with respect to vaccines in Africa: market dynamics, procurement mechanisms, technical feasibility and financing and funding

DELIVERABLES

1. VMPPA study report
2. Peer-reviewed journal publication

STATUS

1. Completed and will be published on AVMI, WHO and UNIDO websites shortly
2. On- hold

VMPPA Stage 2: Country Case Studies

SCOPE

Nine countries selected as 'participating countries' in the case studies. Each country case study will focus on building a business case for investment of time, effort and money in establishing vaccine and / or biological production capacity.

DELIVERABLES

1. Position paper
2. Comprehensive 'Case study report'

STATUS

1. Independent consultant has been contracted to start
2. Consultant: Dr Kristopher Howard
3. Pilot case study: to be completed by Q1 2017



VMPA Study 2:

Rationale: Position paper and Case study



Following the success of the VMPA Stage 1 project, it was agreed that **individual country case studies** would be performed

Concomitant with the case study, a **position paper would be developed which sets out a comparison between vaccine manufacturing strategies**, including a financial analysis with consideration of set-up and on-going manufacturing costs in order to provide guidance to relevant Governments and Manufacturers on the feasibility of developing commercial-scale vaccine manufacturing facilities

VMIPA Study 2: Case Studies

Participating countries

1. Countries Participating in Case Studies

1. Egypt	2. Ethiopia	3. Senegal
4. South Africa	5. Tunisia	6. Algeria
7. Guinea	8. Morocco	8. Nigeria

2. Country Case Studies Phased Approach

Phase 1 (Pilot)	South Africa			
Phase 2	Ethiopia	Senegal	Egypt	Tunisia
Phase 3	Algeria	Guinea	Morocco	Nigeria

VMIPA Study 2: Case Studies

Pilot case study



- Case study is expected to be based on ‘ideal’ company, not manufacturer
- Given the market need, what viable options exist for development of a commercially sustainable manufacturer including:
 - review of vaccines that could be manufactured
 - Consideration of type of facility
 - Considerations of costing
 - ‘High volume’ vs ‘low volume’ case examples, i.e . SADC or SA only
 - Key challenges pertinent to the case study
- Given this, it was thought best to **develop the methodology** to be used in a **‘Pilot country case study’** and then roll it out to the rest of the countries
- Ease of access to costing of new facilities, market data etc would facilitate the development of the case study methodology.

VMPPA Stage 3: Integrated Meta Analysis

SCOPE

Using data generated through Stages 1 and 2, develop a set of strategic recommendations with specific actions wrt: products, geographies, partnerships, procurement and market challenges. Advocacy and the role of AVMI to be elaborated.

DELIVERABLES


Report on 'Vaccine Manufacturing and Procurement in Africa: Strategic considerations'

STATUS

Still to be planned

VMPA Study 2: Case Studies

High level timelines



Note: orange blocks are dependent on funding.



**The best time to
plant a tree was
20 years ago.
The second best
time is now.**

– Chinese Proverb

